Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
JP Stock MarketDetailed Quotes
2160 GNI Group
- 3405
- -205-5.68%
20min DelayMarket Closed Dec 30 15:30 JST
170.80BMarket Cap20.57P/E (Static)
3595High3400Low1.34MVolume3560Open3610Pre Close4.70BTurnover386552wk High2.84%Turnover Ratio50.16MShares153752wk Low145.55EPS TTM160.93BFloat Cap4070Historical High20.57P/E (Static)47.26MShs Float13Historical Low165.56EPS LYR5.40%Amplitude--Dividend TTM4.63P/B100Lot Size--Div YieldTTM
About GNI Group Company
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
Company Profile
Symbol2160
Company NameGNI Group
Founded2001-11-20
MarketTSE Growth
Employees839
Fiscal Year Ends12-31
AddressShinjuku Park Tower 3-7-1 Nishi-Shinjuku
Zip Code103-0023
Phone03-6214-3600
Websitewww.gnipharma.com
Company Executives
- Name
- Position
- Salary
- Dr. Ying Luo, PhD
- Director, Representative Executive Officer, President and Chief Executive Officer
- --
- Toshiya Kitagawa
- Director, Executive Officer and Chief Financial Officer
- --
- Sekitani Kazuki
- Director, Executive Officer and Chief Operating Officer
- --
- Ryosuke Matsui
- Director
- --
- Thomas Eastling
- Director
- --
- Zhang Ping
- Independent Director
- --
- Hideaki Sashiwa
- Independent Director
- --
- Kikuchi Kanako
- Independent Director
- --